According to the Saxenda SmPC, treatment should be discontinued if patients do not lose at least 5% of initial body weight after 12 weeks on the 3.0 mg/day dose
From 1 h pi , the proportion of phagocytosing PBMC also increased significantly, probably due to an increased activity of monocytes as phagocytosing cells
Tolerance to GLP-1 medications is not dose-frequency dependent
Specific keystone bacterial strains are shown to be foundational to the gut microbiome, and appear to play a role in appetite regulation, blood sugar metabolism, gut barrier integrity, and overall metabolic resilience
After 12 weeks of treatment with oral semaglutide, energy intake was reduced, control of eating was improved, and patients experienced weight loss and fewer food cravings
Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G